| Predicted Trait | |
| Reported Trait | Neuroblastoma |
| Mapped Trait(s) | neuroblastoma (EFO_0000621) |
| Score Construction | |
| PGS Name | PRS22_NB |
| Development Method | |
| Name | Genome-wide independent SNPs |
| Parameters | r2<0.1 |
| Variants | |
| Original Genome Build | GRCh37 |
| Number of Variants | 22 |
| Effect Weight Type | log(OR) |
| PGS Source | |
| PGS Catalog Publication (PGP) ID | PGP000287 |
| Citation (link to publication) | Testori A et al. Cancer Epidemiol Biomarkers Prev (2022) |
| Ancestry Distribution | |
| Source of Variant Associations (GWAS) | European: 100% 6,303 individuals (100%) |
| PGS Evaluation | African: 100% 1 Sample Sets |
| Study Identifiers | Sample Numbers | Sample Ancestry | Cohort(s) |
|---|---|---|---|
GWAS Catalog: GCST004510 Europe PMC: 28545128 |
6,303 individuals | European | COG |
|
PGS Performance Metric ID (PPM) |
PGS Sample Set ID (PSS) |
Performance Source | Trait |
PGS Effect Sizes (per SD change) |
Classification Metrics | Other Metrics | Covariates Included in the Model |
PGS Performance: Other Relevant Information |
|---|---|---|---|---|---|---|---|---|
| PPM012873 | PSS009587| African Ancestry| 3,619 individuals |
PGP000287 | Testori A et al. Cancer Epidemiol Biomarkers Prev (2022) |
Reported Trait: Neuroblastoma risk | — | — | R²: 0.0203 | — | — |
|
PGS Sample Set ID (PSS) |
Phenotype Definitions and Methods | Participant Follow-up Time | Sample Numbers | Age of Study Participants | Sample Ancestry | Additional Ancestry Description | Cohort(s) | Additional Sample/Cohort Information |
|---|---|---|---|---|---|---|---|---|
| PSS009587 | — | — | [
|
— | African American or Afro-Caribbean (African American) |
— | COG | — |